Differentiating Immune Cells from Human Pluripotent Stem Cells in Feeder- and Serum-Free Cultures
Obtaining a high yield of immune cells for cell therapy research and immunotherapy development can be challenging. Current workflows are often sub-optimal; their reliance on the use of serum and feeder cells leaves them prone to variability. In addition, the need for autologous cell sources adds further uncertainty and complexity. This can increase the risk of delays, high costs, and issues with getting approvals from regulatory bodies. Researchers must consider every step of their workflow when optimizing protocols to enhance consistency and performance.
In this Innovation Showcase talk from ISSCR 2023, Drs. Nooshin Tabatabaei-Zavareh and Patrick Brauer from STEMCELL Technologies introduce tools that offer optimal conditions for generating immune cells from alternative cell sources, including cord blood-derived hematopoietic stem & progenitor cells or pluripotent stem cells. Our media and supplements have been developed using defined materials and protocols without the use of serum or feeder cells, facilitating the generation of high-quality cell products required in clinical applications.
As a sponsor of, and participant in, ISSCR’s 2023 Annual Meeting, we share with you our Innovation Showcase presentation at #ISSCR2023. This presentation does not represent an endorsement from or support of the ISSCR.
In this Innovation Showcase talk from ISSCR 2023, Drs. Nooshin Tabatabaei-Zavareh and Patrick Brauer from STEMCELL Technologies introduce tools that offer optimal conditions for generating immune cells from alternative cell sources, including cord blood-derived hematopoietic stem & progenitor cells or pluripotent stem cells. Our media and supplements have been developed using defined materials and protocols without the use of serum or feeder cells, facilitating the generation of high-quality cell products required in clinical applications.
As a sponsor of, and participant in, ISSCR’s 2023 Annual Meeting, we share with you our Innovation Showcase presentation at #ISSCR2023. This presentation does not represent an endorsement from or support of the ISSCR.
Publish Date:
July 31, 2023
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
From hPSCs to Immune Cells: Generating Dendritic Cells by Direct Cell Reprogramming
Publish Date: February 10, 2022 -
Quality by Design: Reagents and Support for hPSC-Derived Cell and Gene Therapies
Publish Date: August 16, 2021 -
Accelerating T Cell Therapy Research
Publish Date: October 29, 2021
Explore Our Products
-
For differentiation of human ES or iPS cells into hematopoietic progenitor cells -
For expansion and differentiation of hPSCs to T cells -
STEMdiff™ Hematopoietic - EB Basal Medium
Serum-free medium for the generation of embryoid bodies for downstream lymphoid differentiation -
For expansion and differentiation of hPSCs to NK cells
